BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mantle Cell Lymphoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Mantle Cell Lymphoma\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06656221-3125@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06656221)
DESCRIPTION:Bortezomib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Prospect
 ive\, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab
  Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Man
 tle Cell Lymphoma\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06656221
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504199-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06504199)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Obinutuz
 umab\, Zanubrutinib\, and Lenalidomide Followed Short-Cycle of Obinutuzuma
 b and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06504199
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115631-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04115631)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Compa
 rison of Three Chemotherapy Regimens for the Treatment of Patients With Ne
 wly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4115631
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504199-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06504199)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Obinutuzumab\, Zanubrutinib\, and Lenalidomide Followed Short-Cycle of 
 Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06504199
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05214183-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05214183)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lympho
 ma\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05214183
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05861050-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05861050)
DESCRIPTION:Lenalidomide\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Glofit
 amab With Obinutuzumab\, Venetoclax\, and Lenalidomide for the Treatment o
 f Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma\nEstimated 
 primary completion: 1 February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05861050
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04484012-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04484012)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Modifie
 d Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of R
 elapsed or Refractory Mantle Cell Lymphoma\nEstimated primary completion: 
 23 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aca
 labrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04484012
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522386-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06522386)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: GATE1: 
 A Multicenter Phase II Study of Pirtobrutinib\, Rituximab and Venetoclax C
 ombination Therapy for Patients With Previously Untreated Mantle Cell Lymp
 homa\nEstimated primary completion: 28 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06522386
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03710772)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib\,
  Rituximab\, Venetoclax\, and Combination Chemotherapy in Treating Patient
 s With Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion:
  22 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03710772
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03153202-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03153202)
DESCRIPTION:Ibrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Study to 
 Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizuma
 b in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymph
 oma (MCL)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03153202
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05529069-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05529069)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase I
 I Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantl
 e Cell Lymphoma) Patients\nEstimated primary completion: 28 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05529069
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523975-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270624
DTEND;VALUE=DATE:20270625
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03523975)
DESCRIPTION:Lenalidomide\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Veneto
 clax\, Lenalidomide and Rituximab in Patients With Previously Untreated Ma
 ntle Cell Lymphoma\nEstimated primary completion: 24 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03523975
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855695-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT04855695)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Avo I
 n R/R And Previously Untreated MCL\nEstimated primary completion: 30 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04855
 695
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02427620-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT02427620)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib\,
  Rituximab\, and Consolidation Chemotherapy in Treating Young Patients Wit
 h Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02427
 620
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04189757-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04189757)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04189757
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054776-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06054776)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib\, Obinutuzumab\, and Glofitamab for the Treatment of Relapsed or Re
 fractory Mantle Cell Lymphoma\nEstimated primary completion: 13 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06054776
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261163-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07261163)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Obinutuz
 umab\, Zanubrutinib\, and Lenalidomide in First-line Treatment of Mantle C
 ell Lymphoma\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07261163
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261163-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07261163)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Obinutuzumab\, Zanubrutinib\, and Lenalidomide in First-line Treatment 
 of Mantle Cell Lymphoma\nEstimated primary completion: 31 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07261163
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04234061-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT04234061)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Clinical Tr
 ial to Assess The Efficacy and Safety of the Combination of Tisagenlecleuc
 el And Ibrutinib in Mantle Cell Lymphoma\nEstimated primary completion: 1 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04234061
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04662255-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pirtobrutinib: Phase 3 readout est. (NCT04662255)
DESCRIPTION:Pirtobrutinib\, phase 3\, Mantle Cell Lymphoma.\nStudy: Study o
 f BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients W
 ith Mantle Cell Lymphoma (MCL)\nEstimated primary completion: November 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04662255
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357676-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT06357676)
DESCRIPTION:Ibrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Glofitama
 b Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mant
 le Cell Lymphoma\, IGNITE MCL Trial\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06357
 676
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136351-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06136351)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: A Study of the Zanubrutinib Given in Combination With Bendamustine and 
 Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Pat
 ients With Newly Diagnosed Mantle Cell Lymphoma\nEstimated primary complet
 ion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06136351
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082686-2932@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mesutoclax: Phase 2 readout est. (NCT07082686)
DESCRIPTION:Mesutoclax\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study to
  Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or 
 Refractory Mantle Cell Lymphoma (APEX-06)\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesutoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07082686
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427213-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06427213)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: This is a Phase II\, Open-label\, Multicentre Study of Zanubrutinib-con
 taining Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma\nEs
 timated primary completion: 30 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06427213
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460362-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07460362)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Glofitam
 ab Combined With Lenalidomide in High Risk Patients With Relapsed or Refra
 ctory Mantle Cell Lymphoma\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07460362
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029737-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07029737)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  to Evaluate Acalabrutinib\, in Combination With the R-CHOP Standard of Ca
 re\, for Previously Untreated Mantle Cell Lymphoma in Spain\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07029737
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207785-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07207785)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Pirtobr
 Utinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Ce
 ll Lymphoma\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07207785
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03946878-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03946878)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Venetoc
 lax and Acalabrutinib in Treating Patients With Relapsed or Refractory Man
 tle Cell Lymphoma\nEstimated primary completion: 8 February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03946878
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03282396-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT03282396)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib i
 n Treating Participants With Untreated High Risk Smoldering Mantle Cell Ly
 mphoma\nEstimated primary completion: 28 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03282396
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: ALX148\
 , Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive 
 B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 21 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05025800
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558604-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06558604)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-r
 isk Mantle-cell Lymphoma\nEstimated primary completion: May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06558604
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029309-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06029309)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Mantle Cell Lymphoma.\nSt
 udy: Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma\nEstimated prima
 ry completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06029309
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01880567-2041@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT01880567)
DESCRIPTION:Ibrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Ibrutinib a
 nd Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell 
 Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma\nEsti
 mated primary completion: 31 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT01880567
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252675-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06252675)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Glofita
 mab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma\nEs
 timated primary completion: 31 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06252675
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants With 
 Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle Cel
 l Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839053-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06839053)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Sonrotoclax\, Rituximab\, and Zanubrutinib in Treating Participants Wit
 h Chronic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, and Mantle C
 ell Lymphoma\nEstimated primary completion: 1 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06839053
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765111-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04765111)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib and Rituximab for the Treatment of Previously Untreated Mantle Cell
  Lymphoma\nEstimated primary completion: 30 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04765111
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742996-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beqalzi (Sonrotoclax): Phase 3 readout est. (NCT06742996)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 3\, Mantle Cell Lymphoma.\nStudy:
  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubr
 utinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Ref
 ractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)\nEstimated primary completi
 on: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 onrotoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06742996
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566887-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04566887)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma\nEstimated
  primary completion: September 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04566887
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799220-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07799220)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  A Study of Zanubrutinib\, Obinutuzumab\, and Sonrotoclax in People With M
 antle Cell Lymphoma\nEstimated primary completion: September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07799220
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799220-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07799220)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: A Study of Zanubrutinib\, Obinutuzumab\, and Sonrotoclax in People With
  Mantle Cell Lymphoma\nEstimated primary completion: September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07799220
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05635162-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05635162)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymp
 homa\nEstimated primary completion: October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05635162
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684950-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07684950)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Lisafto
 clax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma Aft
 er BTK-Targeted Therapy\nEstimated primary completion: 30 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07684950
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951959-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05951959)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treat
 ment Naïve Mantle Cell Lymphoma\nEstimated primary completion: 31 October
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595
 1959
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263491-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06263491)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase I
 I Study of Pirtobrutinib\, Rituximab (PR) in Previously Untreated Low and 
 Intermediate Risk MCL (Mantle Cell Lymphoma) Patients\nEstimated primary c
 ompletion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06263491
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944651-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281208
DTEND;VALUE=DATE:20281209
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07944651)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refra
 ctory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure\nEstim
 ated primary completion: 8 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07944651
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944651-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20281208
DTEND;VALUE=DATE:20281209
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07944651)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Pirtobr
 utinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Ma
 ntle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure\nEstimated pri
 mary completion: 8 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pirtobrutinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07944651
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06553872-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT06553872)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Phase 2
  Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleuce
 l in R/R MCL\nEstimated primary completion: August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pirtobrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06553872
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854003-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT06854003)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  BRAZAN: A Randomized Phase 2 Study of Bendamustine\, Rituximab\, Cytarabi
 ne (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Ri
 tuximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lympho
 ma\nEstimated primary completion: 1 November 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06854003
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854003-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06854003)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: BRAZAN: A Randomized Phase 2 Study of Bendamustine\, Rituximab\, Cytara
 bine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/
 Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymp
 homa\nEstimated primary completion: 1 November 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06854003
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Beqalzi (Sonrotoclax): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 1/2\, Mantle Cell Lymphoma.\nStud
 y: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) Whe
 n Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEstim
 ated primary completion: 30 November 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697184-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Brukinsa (zanubrutinib): Phase 1/2 readout est. (NCT06697184)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 1/2\, Mantle Cell Lymphoma.\nSt
 udy: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) W
 hen Initiating Sonrotoclax in Participants Treated for Blood Cancers.\nEst
 imated primary completion: 30 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06697184
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910801-3126@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05910801)
DESCRIPTION:Lenalidomide\, phase 2\, Mantle Cell Lymphoma.\nStudy: Tafasita
 mab\, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refract
 ory Mantle Cell Lymphoma\nEstimated primary completion: 30 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05910801
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341191-2909@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Beqalzi (Sonrotoclax): Phase 2 readout est. (NCT07341191)
DESCRIPTION:Beqalzi (Sonrotoclax)\, phase 2\, Mantle Cell Lymphoma.\nStudy:
  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle
  Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy\nEstimated 
 primary completion: 31 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sonrotoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07341191
URL:https://assetmemo.bio/drug/sonrotoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341191-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07341191)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Mantle Cell Lymphoma.\nStud
 y: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mant
 le Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07341191
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: A Stu
 dy of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents 
 for Mature B-Cell Malignancies\nEstimated primary completion: 20 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833763-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT05833763)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Phase
  2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients 
 With Prior BTK Inhibitor Exposure.\nEstimated primary completion: April 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrutinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0583376
 3
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784101-2932@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07784101)
DESCRIPTION:Mesutoclax\, phase 3\, Mantle Cell Lymphoma.\nStudy: A Phase 3 
 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib
  Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle C
 ell Lymphoma (r/r MCL).\nEstimated primary completion: October 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/mesutoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784101
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285590-3359@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Pirtobrutinib: Phase 2 readout est. (NCT07285590)
DESCRIPTION:Pirtobrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Clinica
 l Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituxima
 b in Patients With Mantle Cell Lymphoma\nEstimated primary completion: Dec
 ember 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirtobrut
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07285590
URL:https://assetmemo.bio/drug/pirtobrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910435-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07910435)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Polatuz
 umab Vedotin\, Mosunetuzumab\, and Acalabrutinib for the Treatment of Mant
 le Cell Lymphoma\, PAcMan Trial\nEstimated primary completion: 1 January 2
 033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079104
 35
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846489-3339@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20330210
DTEND;VALUE=DATE:20330211
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06846489)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate
 -Risk Younger Untreated Mantle Cell Lymphoma\nEstimated primary completion
 : 10 February 2033. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 calabrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06846489
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976763-10908@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20380831
DTEND;VALUE=DATE:20380901
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05976763)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Mantle Cell Lymphoma.\nStud
 y: Testing Continuous Versus Intermittent Treatment With the Study Drug Za
 nubrutinib for Older Patients With Previously Untreated Mantle Cell Lympho
 ma\nEstimated primary completion: 31 August 2038. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05976763
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
